# Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

> **NCT06900595** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (estimated)

## Conditions studied

- Locally Advanced Adrenal Cortical Carcinoma
- Metastatic Adrenal Cortical Carcinoma
- Recurrent Adrenal Cortical Carcinoma
- Stage III Adrenal Cortical Carcinoma AJCC v8
- Stage IV Adrenal Cortical Carcinoma AJCC v8
- Unresectable Adrenal Cortical Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib
- **BIOLOGICAL:** Cemiplimab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06900595
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-22
- **Primary completion:** 2029-06-02
- **Final completion:** 2029-06-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06900595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06900595, "Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06900595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*